Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines presented Phase 1/2 data at ESMO GI for zoldonrasib combinations in RAS G12D metastatic pancreatic cancer, showing an 82% objective response rate with modified FOLFIRINOX and 61% with gemcitabine plus nab-paclitaxel in first-line patients. In previously treated patients, the combination of zoldonrasib and daraxonrasib demonstrated a 50% ORR in second-line and 47% in third-line-plus cohorts, with median progression-free survival of 9.6 months and 7.6 months respectively.
Key figures
- Median pfs 2l
- 9.6 months
- Grade 3 traes gnp
- 80%
- Grade 3 traes mffx
- 61%
- Median pfs 3l plus
- 7.6 months
- Dcr zoldonrasib gnp
- 90%
- Grade 3 traes combo
- 35%
- Orr zoldonrasib gnp
- 61%
- Dcr zoldonrasib mffx
- 96%
- Orr zoldonrasib mffx
- 82%
- Dcr zoldonrasib daraxonrasib 2l
- 97%
- Orr zoldonrasib daraxonrasib 2l
- 50%
- Dcr zoldonrasib daraxonrasib 3l plus
- 90%
- Orr zoldonrasib daraxonrasib 3l plus
- 47%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.